Editas Medicine (EDIT) Cash from Investing Activities (2015 - 2025)

Editas Medicine (EDIT) has reported Cash from Investing Activities for 11 consecutive years, with $39.6 million the latest figure, recorded in Q3 2025.

• In Q3 2025, Cash from Investing Activities fell 52.88% year-over-year to $39.6 million; the TTM figure through Sep 2025 stood at $169.6 million (down 12.61% YoY), while the FY2024 annual figure was $162.1 million, up 4445.91% from the prior year.
• Cash from Investing Activities fell to $39.6 million in Q3 2025 per EDIT's latest filing, from $42.6 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $89.2 million in Q3 2022 and bottomed at -$102.8 million in Q3 2023.
• Historically, Cash from Investing Activities has averaged $18.8 million across 5 years, with a median of $23.3 million in 2023.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities surged 1637.7% — and 2023, when it plunged 215.23%.
• Editas Medicine's Cash from Investing Activities stood at -$22.8 million in 2021, then fell by 20.53% to -$27.5 million in 2022, then surged by 328.28% to $62.8 million in 2023, then tumbled by 50.74% to $31.0 million in 2024, then gained by 27.83% to $39.6 million in 2025.
• Business Quant data shows EDIT's Cash from Investing Activities at $39.6 million in Q3 2025, $42.6 million in Q2 2025, and $56.4 million in Q1 2025.